CYP2D6Your two copies: *4/*4
Poor metabolizer
Neither copy works.
0.0 activity scoreTypical: 1.25 to 2.25Turns on or clears about 1 in 4 prescription drugs. These include many drugs for depression, pain and ADHD.
This result changes the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Oncology · Estrogen ModulatorsExample report
Tamoxifen
Nolvadex, Soltamox
Consider alternative
Your body makes very little of this drug's active form, so it may not work well to stop breast cancer from coming back. Another hormone therapy is advised.
The genes behind this label
The guidelines read one gene for tamoxifen. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
CYP2D6Poor metabolizer
CPIC guideline
Evidence: strongRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- Your body makes very little of this drug's active form, so it may not work well to stop breast cancer from coming back. Another hormone therapy is advised.
- What it means
- Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.
- What the guideline suggests
- Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.
About tamoxifen
Tamoxifen is a hormonal therapy for estrogen receptor-positive breast cancer, used after surgery to lower the chance of recurrence, for advanced disease, and to reduce breast cancer risk in women at high risk.
- Used for
- Estrogen receptor-positive breast cancer: treatment after surgery (adjuvant) and of metastatic disease; reducing the risk of invasive breast cancer after DCIS and in women at high risk
Others in oncology
Compare all 13 oncology- BelinostatBeleodaq Use as directed
- BelzutifanWelireg Use as directed
- CapecitabineXeloda, Xitabin, Kapetral Use as directed
- ErdafitinibBalversa Use as directed
- FluorouracilAdrucil, Carac Use as directed
- GefitinibIressa Use with caution
- IrinotecanCamptosar, Onivyde Use as directed
- MercaptopurinePurinethol Use as directed
Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.